Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Research & Development for 17 consecutive years, with $326.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 33.73% year-over-year to $326.7 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 billion (up 27.36% YoY), and the FY2025 full-year result was $1.0 billion, up 38.93% from the prior year.
• Research & Development climbed to $326.7 million in Q2 2026 per NBIX's latest filing, from $296.2 million in the prior quarter.
• Across five years, Research & Development topped out at $326.7 million in Q2 2026 and bottomed at $102.2 million in Q1 2022.
• Historically, Research & Development has averaged $188.8 million across 5 years, with a median of $172.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 81.68% in 2022, then grew 7.28% in 2023.
• Over 5 years, Research & Development stood at $118.0 million in 2022, then gained by 16.53% to $137.5 million in 2023, then surged by 34.98% to $185.6 million in 2024, then surged by 39.12% to $258.2 million in 2025, then grew by 26.53% to $326.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $326.7 million, $296.2 million, and $258.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.